ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM
Tecvayli + Darzalex delivers superior efficacy in early relapsed MM, positioning J&J to dominate the R/R market.
Therapy Area
New HBV vaccine guidance likely to increase infection among newborns
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Belite eyes tinlarebant approval after late-stage Stargardt success
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
